Sheet

APR 1 5 2002

PTO/SB/08A (08-00) U.S. Paterit and Trademark Office: U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a pair EMP control pumple.

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are Substitute for form 1449A/PTQ

INFORMATION DISCLOSURER 1 5 2002 STATEMENT BY APPLICANT

(use as many sheets as the essary)

of

SOEN POY 08/908,867 **Application Number** August 8, 1997 Filing Date **First Named Inventor** Young

Group Art Unit 1642 Holleran

**Examiner Name** Attorney Docket Number 030639.0040.CIP1

				U.S. PATENT DOCU	MENTS	. *	60	lo-J
Examiner	Cite	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant		7.0
Initials*	No.1	Number	Number Kind Code <sup>2</sup> of (if known)	of Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	290	
			*	*			0	

	FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent Doc Number <sup>4</sup>	ument Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>		
KAC	5	wo	98/30231		Amylin Pharmaceuticals, Inc.	07-16-1998				
KAL	- 7	wo	99/07404		Amylin Pharmaceuticals, Inc.	02-18-1999				

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.						
KAV	(	BAYER et al., "Advances in Poison Management," Clin. Chem., 42(8)(B):1361-66 (1996)						
	\	D'ALESSIO et al., "Glucagon-like Peptide 1 Enhances Glucose Tolerance Both by Stimulation of Insulin Release and by Increasing Insulin-independent Glucose Disposal," J. Clin. Invest., 93:2263-66 (1994)						
		HOLST, "Glucagonlike Peptide-1: A Newly Discovered Gastrointestinal Hormone," Gastroenterology, 107:1848-55 (1994)						
1	\	LAWLER et al., "Comparison of Effects of Amylin, Glucagon-like Peptide-1 (GLP-1) and Exendin-4 to Inhibit Pentagastrin-Stimulated Gastric Acid Secretion in Rats," Gastroenterology, 112(4):A194, (1997)						

					_
Examiner Signature	Jaron G.	Canella	Date Considered	12/9/03	
					_

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Intitial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

KAC	MIHOLIC et al., "Glucagon-like Peptide-1 (GLP-1), Entleerung des Magenersatzes und das Dumpingsyndrom nach Gastrektomie," Chirurgishes Forum, 1991, pp. 429-32 (English abstract and International Search Report in which the article is referenced are attached)  NAUCK et al., "Effects of Subcutaneous Glucagon-like Peptide 1 (GLP-1 [7-36 Amide]) in Patients with Type 2-Diabetes," Diabetologia, Abstract A148, 38 Supp. 1:A39 (1995)  ORSKOV et al., "Is the Effect of Glucagon-like Peptide-1 on Gastric Emptying Centrally Mediated?", Diabetologia, Abstract A147, 38 Supp. 1:A39, (1995)  RITZEL et al., "GLP-1 [7-36 Amide] Augments Bisphasic Insulin Secretion After Intravenous Glucose in Healthy Volunteers," Diabetologia, Abstract A145, 38 Supp. 1:A39, (1995)	HANN II ST CLIMA
-		

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

+

JE JC87
JE JE JE Sheet

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

2

C	RECE	VE	
Application Number	08/908,867	- HEOF	
Filing Date	April 10, 2002		2003
First Named Inventor	Young	JANO	2000
Group Art Unit	1642		1000
Examiner Name	Holleran		k 160(
Attorney Docket Number	030639.0040.CPA1	JEOU OF !!	_ λ =

				U.S. PATENT DOCU	MENTS	
Examiner Initials*	Cite No.'	U.S. Pater Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
e.						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent Doo Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>	
KAL	-	WO	98/05351		Amylin Pharmaceuticals, Inc.	02-12-1998			

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>				
KAC		NAVARRO, M. et al., "Colocalization of Glucagon-Like Peptide-1 (GLP-1) Receptors, Glucose Transporter GLUT-2, and Glucokinase mRNAs in Rat Hypothalamic Cells: Evidence for a Role of GLP-1 Receptor Agonists as an Inhibitory Signal for Food and Water Intake," <u>Journal of Neurochemistry</u> , 67:1982-1991 (1996)					

Examiner Signature	aren	A	Gamlla	Date Considered	12/9/03
	<i>T</i>	77	,		· · · · · · · · · · · · · · · · · · ·

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initia if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.